FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W170094209> ?p ?o ?g. }

• W170094209 endingPage "65" @default.
• W170094209 startingPage "57" @default.
• W170094209 abstract "Limited information is available on the activity of antiretroviral drugs against human immunodeficiency virus type 2 (HIV-2) and simian immunodeficiency virus (SIV) strains to guide their use in treatment or prophylaxis. We evaluated the antiviral activity of 16 approved drugs and one experimental drug, AMD3100, against two wild-type HIV-2 (ROD and EHO) isolates, two strains of SIV (mac251 and B670), and two strains of simian-human immunodeficiency virus (SHIV) that contain the reverse transcriptase (RTSHIV) or envelope glycoprotein (SHIV89.6) of human immunodeficiency virus type 1 (HIV-1) in a SIV(mac239) background. Drug susceptibility was measured conventionally by the MT-4/MTT assay, and results were analysed as fold changes in 50% effective concentration (EC50) relative to the EC50 for HIV-1 (IIIB). The nucleoside reverse transcriptase inhibitors (NRTIs) zidovudine, lamivudine, stavudine, didanosine, zalcitabine and abacavir as well as the nucleotide reverse transcriptase inhibitor tenofovir retained full activity against all six viruses except for SIV and SHIV89.6 that showed low-level resistance to didanosine. The protease inhibitors (PIs) ritonavir, indinavir, saquinavir and nelfinavir were found to be active against some HIV-2 or SIV strains. However, a significant reduction in susceptibility was seen with indinavir against SHIV89.6 (3.3-fold), and with amprenavir against HIV-2(ROD) (8.8-fold). All viruses except for RTSHIV showed a >200-fold decrease in susceptibility for the non-nucleoside reverse transcriptase inhibitors (NNRTIs) nevirapine, delavirdine and efavirenz, indicating high-level resistance. AMD3100, a CXCR4 antagonist, was active against HIV-2 and SHIV89.6, a finding consistent with the use of the CXCR4 co-receptor by these isolates, but was inactive against SIV strains. In contrast, enfuvirtide (T-20) was active against SHIV89.6 but had reduced inhibitory activity against both HIV-2 and SIV strains predicting little therapeutic value against these viruses. These findings support the use of NRTIs, tenofovir, but not NNRTIs, for treating HIV-2-infected persons or for prophylaxis against HIV-2 and SIV. The clinical significance of the low-level resistance of HIV-2 and SIV to some PIs is unclear. Co-receptor antagonists such as AMD3100 show promising anti-HIV-2 therapeutic modalities. Both AMD3100 and enfuvirtide could be used for prophylaxis against SHIV89.6." @default.
• W170094209 created "2016-06-24" @default.
• W170094209 creator A5005405338 @default.
• W170094209 creator A5006602918 @default.
• W170094209 creator A5016741562 @default.
• W170094209 creator A5031077639 @default.
• W170094209 creator A5040662398 @default.
• W170094209 creator A5066053312 @default.
• W170094209 date "2004-01-01" @default.
• W170094209 modified "2023-10-09" @default.
• W170094209 title "Susceptibility of HIV-2, Siv and Shiv to Various Anti-HIV-1 Compounds: Implications for Treatment and Postexposure Prophylaxis" @default.
• W170094209 cites W1537640815 @default.
• W170094209 cites W1586476245 @default.
• W170094209 cites W1659719610 @default.
• W170094209 cites W1837018648 @default.
• W170094209 cites W1968873679 @default.
• W170094209 cites W1977282539 @default.
• W170094209 cites W1977841386 @default.
• W170094209 cites W1979262626 @default.
• W170094209 cites W1981730696 @default.
• W170094209 cites W1986266125 @default.
• W170094209 cites W1991670386 @default.
• W170094209 cites W1994685542 @default.
• W170094209 cites W2004013930 @default.
• W170094209 cites W2018197676 @default.
• W170094209 cites W2019801008 @default.
• W170094209 cites W2043535732 @default.
• W170094209 cites W2052363694 @default.
• W170094209 cites W2063825413 @default.
• W170094209 cites W2084487317 @default.
• W170094209 cites W2095725835 @default.
• W170094209 cites W2125468869 @default.
• W170094209 cites W2143107901 @default.
• W170094209 cites W2157407559 @default.
• W170094209 cites W2168188103 @default.
• W170094209 cites W2328322027 @default.
• W170094209 cites W2330220433 @default.
• W170094209 cites W2334277624 @default.
• W170094209 cites W2407423038 @default.
• W170094209 cites W2416259257 @default.
• W170094209 cites W2466328521 @default.
• W170094209 cites W4232932066 @default.
• W170094209 doi "https://doi.org/10.1177/135965350400900115" @default.
• W170094209 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15040537" @default.
• W170094209 hasPublicationYear "2004" @default.
• W170094209 type Work @default.
• W170094209 sameAs 170094209 @default.
• W170094209 citedByCount "221" @default.
• W170094209 countsByYear W1700942092012 @default.
• W170094209 countsByYear W1700942092013 @default.
• W170094209 countsByYear W1700942092014 @default.
• W170094209 countsByYear W1700942092015 @default.
• W170094209 countsByYear W1700942092016 @default.
• W170094209 countsByYear W1700942092017 @default.
• W170094209 countsByYear W1700942092018 @default.
• W170094209 countsByYear W1700942092019 @default.
• W170094209 countsByYear W1700942092020 @default.
• W170094209 countsByYear W1700942092021 @default.
• W170094209 countsByYear W1700942092022 @default.
• W170094209 countsByYear W1700942092023 @default.
• W170094209 crossrefType "journal-article" @default.
• W170094209 hasAuthorship W170094209A5005405338 @default.
• W170094209 hasAuthorship W170094209A5006602918 @default.
• W170094209 hasAuthorship W170094209A5016741562 @default.
• W170094209 hasAuthorship W170094209A5031077639 @default.
• W170094209 hasAuthorship W170094209A5040662398 @default.
• W170094209 hasAuthorship W170094209A5066053312 @default.
• W170094209 hasBestOaLocation W1700942091 @default.
• W170094209 hasConcept C104317684 @default.
• W170094209 hasConcept C142462285 @default.
• W170094209 hasConcept C156719811 @default.
• W170094209 hasConcept C159047783 @default.
• W170094209 hasConcept C181199279 @default.
• W170094209 hasConcept C2522874641 @default.
• W170094209 hasConcept C2776452011 @default.
• W170094209 hasConcept C2776714187 @default.
• W170094209 hasConcept C2776937687 @default.
• W170094209 hasConcept C2777210460 @default.
• W170094209 hasConcept C2777351918 @default.
• W170094209 hasConcept C2777363262 @default.
• W170094209 hasConcept C2777447569 @default.
• W170094209 hasConcept C2777583353 @default.
• W170094209 hasConcept C2777869810 @default.
• W170094209 hasConcept C2777995582 @default.
• W170094209 hasConcept C2779130552 @default.
• W170094209 hasConcept C2779298103 @default.
• W170094209 hasConcept C2779465607 @default.
• W170094209 hasConcept C2779690655 @default.
• W170094209 hasConcept C2779889181 @default.
• W170094209 hasConcept C2780216070 @default.
• W170094209 hasConcept C2780593183 @default.
• W170094209 hasConcept C2780727368 @default.
• W170094209 hasConcept C2780866839 @default.
• W170094209 hasConcept C2781160516 @default.
• W170094209 hasConcept C2781432083 @default.
• W170094209 hasConcept C2993143319 @default.
• W170094209 hasConcept C55493867 @default.
• W170094209 hasConcept C67705224 @default.

• next